Ameriprise Financial Inc Immunity Bio, Inc. Transaction History

Ameriprise Financial Inc

$356 Billion
Q1 2025

A detailed history of Ameriprise Financial Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 38,804 shares of IBRX stock, worth $112,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,804

Previous 15,014 158.45%

Holding current value

$112,531

Previous $38,000 205.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$2.32 - $3.9 $55,192 - $92,781	23,790 Added 158.45%	38,804 $116,000
Q4 2024 Feb 14, 2025	BUY	$2.56 - $6.17 $38,435 - $92,636	15,014 New	15,014 $38,000
Q2 2024 Aug 14, 2024	SELL	$4.82 - $9.15 $18,605 - $35,319	-3,860 Reduced 25.71%	11,155 $70,000
Q1 2024 May 15, 2024	SELL	$3.23 - $6.17 $19,654 - $37,544	-6,085 Reduced 28.84%	15,015 $80,000
Q4 2023 Feb 14, 2024	BUY	$1.25 - $5.21 $26,375 - $109,931	21,100 New	21,100 $105,000
Q2 2023 Aug 14, 2023	BUY	$1.53 - $6.41 $34,272 - $143,584	22,400 New	22,400 $62,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.77 $295,778 - $460,326	67,995 New	67,995 $344,000
Q4 2021 Feb 14, 2022	SELL	$5.67 - $10.18 $156,577 - $281,120	-27,615 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.17 - $14.24 $4,768 - $7,404	-520 Reduced 1.85%	27,615 $269,000
Q2 2021 Aug 16, 2021	BUY	$13.41 - $22.4 $469 - $784	35 Added 0.12%	28,135 $402,000
Q1 2021 May 17, 2021	BUY	$12.83 - $42.25 $360,523 - $1.19 Million	28,100 New	28,100 $667,000

Others Institutions Holding IBRX

# of Institutions

239

Shares Held

79.9M

Call Options Held

1.08M

Put Options Held

2.73M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.16B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Immunity Bio, Inc. Transaction History